Research

Microsoft shows off watch that quiets Parkinson’s tremors

SAN FRANCISCO — Tech company developer conferences always feature a wacky demo or three.

But at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella’s keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson’s.

After a speech that both heralded and warned about coming leaps in technological power, Nadella screened a video that told the story of two British Microsoft Research employees, Haiyan Zhang and Nicolas Villa, who developed the tremor-interrupting device for a BBC documentary, The Big Life Fix.

Working with graphic designer and Parkinson’s sufferer Emma Lawton, 32, the researchers developed a watch — which they named Emma — that, according to Microsoft, “vibrates in a distinctive pattern to disrupt the feedback loop between brain and hand.”

The video showed Lawton trying to draw a square with her shaky right hand, and then again, wearing Emma. Watson erupts in tears as she calls her mother to say this is the first time she’s been able to write her name in ages.

When the lights went up, Nadella welcomed both Lawton and engineer Zhang on stage, thanking them for showing that thanks “developers can have impact.”

Emma Watch remains a prototype, Microsoft says, but the developers are working with a neuroscience research team to undertake trials with a small group of Parkinson’s sufferers.

The watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft. “Once these symptoms can be identified and measured, it’s possible to develop technology and devices that help humans manage their symptoms. AI is used to classify the sensor information and elicit real-time responses on small devices like wearables.”

Microsoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people. “Rather, its technology has the potential to help Parkinson’s patients manage symptoms that impede regular functions. The goal of further research is to determine whether Emma Watch could help other people with similar Parkinson’s symptoms.”

https://www.usatoday.com/story/tech/talkingtech/2017/05/10/microsoft-shows-off-watch-quiets-parkinsons-tremors/101517718/

Read more

Could Parkinson’s Disease Start in the Gut?

Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. The vagus nerve extends from the brainstem to the abdomen and controls unconscious body processes like heart rate and food digestion.

The preliminary study examined people who had resection surgery, removing the main trunk or branches of the vagus nerve. The surgery, called vagotomy, is used for people with ulcers. Researchers used national registers in Sweden to compare 9,430 people who had a vagotomy over a 40-year period to 377,200 people from the general population. During that time, 101 people who had a vagotomy developed Parkinson’s disease, or 1.07 percent, compared to 4,829 people in the control group, or 1.28 percent. This difference was not significant.

But when researchers analyzed the results for the two different types of vagotomy surgery, they found that people who had a truncal vagotomy at least five years earlier were less likely to develop Parkinson’s disease than those who had not had the surgery and had been followed for at least five years. In a truncal vagotomy, the nerve trunk is fully resected. In a selective vagotomy, only some branches of the nerve are resected.

A total of 19 people who had truncal vagotomy at least five years earlier developed the disease, or 0.78 percent, compared to 3,932 people who had no surgery and had been followed for at least five years, at 1.15 percent. By contrast, 60 people who had selective vagotomy five years earlier developed Parkinson’s disease, or 1.08 percent. After adjusting for factors such as chronic obstructive pulmonary disease, diabetes, arthritis and other conditions, researchers found that people who had a truncal vagotomy at least five years before were 40 percent less likely to develop Parkinson’s disease than those who had not had the surgery and had been followed for at least five years.

“These results provide preliminary evidence that Parkinson’s disease may start in the gut,” said study author Bojing Liu, MSc, of the Karolinska Instituet in Stockholm, Sweden. “Other evidence for this hypothesis is that people with Parkinson’s disease often have gastrointestinal problems such as constipation, that can start decades before they develop the disease. In addition, other studies have shown that people who will later develop Parkinson’s disease have a protein believed to play a key role in Parkinson’s disease in their gut.”

The theory is that these proteins can fold in the wrong way and spread that mistake from cell to cell.

“Much more research is needed to test this theory and to help us understand the role this may play in the development of Parkinson’s,” Liu said. Additionally, since Parkinson’s is a syndrome, there may be multiple causes and pathways.

Even though the study was large, Liu said one limitation was small numbers in certain subgroups. Also, the researchers could not control for all potential factors that could affect the risk of Parkinson’s disease, such as smoking, coffee drinking or genetics.

The study was supported by the Swedish Research Council for Health, Working Life and Welfare, the Parkinson Research Foundation in Sweden, and the U.S. National Institutes of Health.

To learn more about Parkinson’s disease, visit www.aan.com/patients.

The American Academy of Neurology is the world’s largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, concussion, Parkinson’s disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+, LinkedIn and YouTube.

http://www.newswise.com/articles/could-parkinson-s-disease-start-in-the-gut

Read more

31st Annual Parkinson Disease Symposium | June 23, 2017

WPA will host its 31st Annual Parkinson Disease Symposium on Friday, June 23, 2017 at Country Springs Hotel & Conference Center in Pewaukee, Wisconsin.

Beginning at 8:00am, attendees can check in and visit with vendors at the Resource Fair where health and community agencies will display valuable information throughout the day. Beginning at 9:00am, the first main session will be “Understanding Parkinson Disease from a Scientific Perspective”, presented by Giuseppe P. Cortese, PhD, Postdoctoral Research Associate, Department of Neurology, University of Wisconsin-Madison. The morning breakout sessions will follow Dr. Cortese’s interactive presentation, and participants will choose from three options: “Caregivers: Being prepared for an emergency”, “Grieving ‘life as we have known it’”, and a Panel on PD exercise programs.

During lunch, the resource fair will again be open for participants. After lunch, the afternoon breakout sessions will include “Are you caring too much and laughing too little?”, “Causes and prevention of falls” and “Exercise: A targeted attack on Parkinson’s.” The closing session for all attendees will be “Nutrition for Parkinson Disease” presented by Michelle McDonagh, RD, CD, Froedtert & The Medical College of Wisconsin. The Symposium will conclude by 3:30pm.

The registration fee is $30 per person and includes educational materials, continental breakfast, and lunch. To register, CLICK HERE or call our office at 414-312-6990. Registration is required and must be received by Wednesday, June 14.

The event is sponsored by Abbvie, Medtronic and US WorldMeds.

Read more

Study Making Strides Toward Parkinson’s Biomarker

At the current time, there is no identified biomarker for Parkinson’s disease (PD). In other words, there is no objective measure — no lab or imaging test, for example — that can tell whether a person has PD, what type of motor and non-motor symptoms will predominate and how those symptoms will change over time.

Having a biomarker for Parkinson’s would both inform clinical care and accelerate research. A key potential biomarker is alpha-synuclein, the sticky protein that clumps in the brains of people with PD. These protein clumps — called Lewy bodies — are a hallmark of the disease thought to cause damage or death to dopamine-producing brain cells. Researchers can’t currently visualize alpha-synuclein in the brains of people with PD while they’re living. (This is, however, a priority area for the Foundation and MJFF is funding efforts to develop an agent to image alpha-synuclein in the brain.) They can, however, measure the protein in several areas outside of the brain, as alpha-synuclein is found throughout the body.

Researchers haven’t yet determined the optimal location(s) or method(s) to sample alpha-synuclein. To meet this need, in 2016, MJFF launched the Systemic Synuclein Sampling Study (S4), an observational clinical study involving 60 people at varied stages of Parkinson’s disease and 20 healthy volunteers. A new report, published in Biomarkers in Medicine, details the study’s procedures and goals. The article describes the standardized collection and analysis protocols used to measure alpha-synuclein in each participant’s spinal fluid, saliva and blood, as well as their skin, colon and salivary gland tissues.

S4 is the first study to evaluate alpha-synuclein in multiple body fluids and tissues within the same person and across a population of people at various points in PD. These results may lead to recommendations for optimal alpha-synuclein measurements in clinical trial participants as well as an understanding of how alpha-synuclein changes throughout the disease course.

As the study authors write, “The development of a peripheral alpha-synuclein biomarker would provide a valuable tool for confirming the diagnosis of PD, and possibly identification of the disease in its earliest stages, and provide a potential means of monitoring efficacy of potential disease modifying agents.”

A tool that could facilitate diagnosis and gauge the impact of therapies in development would truly change the way we’re able to conduct research and how quickly we can move therapies through the pipeline. That’s why finding a biomarker and research such as this are so critical.

Visit Fox Trial Finder to learn more about how you can participate in S4 and other Parkinson’s research studies.

https://www.michaeljfox.org/foundation/news-detail.php?mjff-study-making-strides-toward-parkinson-biomarker

Read more